Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease

Experimental Neurology

Volumn 232, Issue 2, 2011, Pages 261-269

  Jablonka, Sibylle ^a   Holtmann, Bettina ^a   Sendtner, Michael ^a   Metzger, Friedrich ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Motoneuronopathy; Motor neuron disease; Neuromuscular disorder; PEGylated IGF 1

Indexed keywords

MACROGOL; PEGYLATED INSULIN LIKE GROWTH FACTOR 1; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; EMBRYO; EMBRYO CELL; IN VITRO STUDY; IN VIVO STUDY; MOTOR COORDINATION; MOTOR NEURON DISEASE; MOUSE; MOUSE MUTANT; MOUSE STRAIN; MUSCLE FORCE; MUSCLE FUNCTION; NERVE CELL DEGENERATION; NERVE FIBER; NERVE FIBER GROWTH; NERVE FUNCTION; NEUROMUSCULAR DISEASE; NONHUMAN; PHRENIC NERVE; PMN MOUSE; PRIORITY JOURNAL; WEIGHT REDUCTION; WILD TYPE;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG DESIGN; FEMALE; FETUS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; MOTOR NEURON DISEASE; MOTOR NEURONS; NERVE FIBERS, MYELINATED; PHRENIC NERVE; POLYETHYLENE GLYCOLS; PREGNANCY; RECOMBINANT PROTEINS; SPINAL CORD;

EID: 80054996039     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.09.015     Document Type: Article

References (57)

1. Alcántara S., Frisén J., del Río J.A., Soriano E., Barbacid M., Silos-Santiago I. TrkB signaling is required for postnatal survival of CNS neurons and protects hippocampal and motor neurons from axotomy-induced cell death. J. Neurosci. 1997, 17:3623-3633.
2. Basu A., Yang K., Wang M., Liu S., Chintala R., Palm T., Zhao H., Peng P., Wu D., Zhang Z., Hua J., Hsieh M.C., Zhou J., Petti G., Li X., Janjua A., Mendez M., Liu J., Longley C., Zhang Z., Mehlig M., Borowski V., Viswanathan M., Filpula D. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug. Chem. 2006, 17:618-630.
3. Bömmel H., Xie G., Rossoll W., Wiese S., Jablonka S., Boehm T., Sendtner M. Missense mutation in the tubulin-specific chaperone E (Tbce) gene in the mouse mutant progressive motor neuronopathy, a model of human motoneuron disease. J. Cell Biol. 2002, 159:563-569.
4. Borasio G.D., Robberecht W., Leigh P.N., Emile J., Guiloff R.J., Jerusalem F., Silani V., Vos P.E., Wokke J.H., Dobbins T. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I study group. Neurology 1998, 51:583-586.
5. Bordet T., Schmalbruch H., Pettmann B., Hagege A., Castelnau-Ptakhine L., Kahn A., Haase G. Adenoviral cardiotrophin-1 gene transfer protects pmn mice from progressive motor neuronopathy. J. Clin. Invest. 1999, 104:1077-1085.
6. Boura-Halfon S., Zick Y. Serine kinases of insulin receptor substrate proteins. Vitam. Horm. 2009, 80:313-349.
7. Boyd J.G., Gordon T. The neurotrophin receptors, trkB and p75, differentially regulate motor axonal regeneration. J. Neurobiol. 2001, 49:314-325.
8. Dodge J.C., Haidet A.M., Yang W., Passini M.A., Hester M., Clarke J., Roskelley E.M., Treleaven C.M., Rizo L., Martin H., Kim S.H., Kaspar R., Taksir T.V., Griffiths D.A., Cheng S.H., Shihabuddin L.S., Kaspar B.K. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol. Ther. 2008, 16:1056-1064.
9. Dodge J.C., Treleaven C.M., Fidler J.A., Hester M., Haidet A., Handy C., Rao M., Eagle A., Matthews J.C., Taksir T.V., Cheng S.H., Shihabuddin L.S., Kaspar B.K. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther. 2010, 18:2075-2084.
10. Duong F., Fournier J., Keane P.E., Guénet J.L., Soubrié P., Warter J.M., Borg J., Poindron P. The effect of the nonpeptide neurotrophic compound SR 57746A on the progression of the disease state of the pmn mouse. Br. J. Pharmacol. 1998, 124:811-817.
11. Ferrer-Alcon M., Winkler-Hirt C., Madani R., Perrin F.E., Kato A.C. Low intensity exercise attenuates disease progression and stimulates cell proliferation in the spinal cord of a mouse model with progressive motor neuronopathy. Neuroscience 2008, 152:291-295.
12. Ferri A., Sanes J.R., Coleman M.P., Cunningham J.M., Kato A.C. Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Curr. Biol. 2003, 13:669-673.
13. Festoff B.W., Yang S.X., Vaught J., Bryan C., Ma J.Y. The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies. J. Neurol. Sci. 1995, 129(suppl):114-121.
14. Franz C.K., Federici T., Yang J., Backus C., Oh S.S., Teng Q., Carlton E., Bishop K.M., Gasmi M., Bartus R.T., Feldman E.L., Boulis N.M. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol. Dis. 2009, 33:473-481.
15. Gregorevic P., Plant D.R., Leeding K.S., Bach L.A., Lynch G.S. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am. J. Pathol. 2002, 161:2263-2272.
16. Haase G., Pettmann B., Vigne E., Castelnau-Ptakhine L., Schmalbruch H., Kahn A. Adenovirus-mediated transfer of the neurotrophin-3 gene into skeletal muscle of pmn mice: therapeutic effects and mechanisms of action. J. Neurol. Sci. 1998, 160(suppl):S97-105.
17. Hantaï D., Akaaboune M., Lagord C., Murawsky M., Houenou L.J., Festoff B.W., Vaught J.L., Rieger F., Blondet B. Beneficial effects of insulin-like growth factor-I on wobbler mouse motoneuron disease. J. Neurol. Sci. 1995, 129(suppl.):122-126.
18. Harris J.M., Chess R.B. Effect of PEGylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2:214-221.
19. Hinds K.D., Kim S.W. Effect of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 2002, 54:505-530.
20. Hirokawa N., Takemura R. Molecular motors and mechanisms of directional transport in neurons. Nat. Rev. Neurosci. 2005, 6:201-214.
21. Holtmann B., Zielasek J., Toyka K.V., Sendtner M. Comparative analysis of motoneuron loss and functional deficits in PMN mice: implications for human motoneuron disease. J. Neurol. Sci. 1999, 169:140-147.
22. Hughes R.A., Sendtner M., Thoenen H. Members of several gene families influence survival of rat motoneurons in vitro and in vivo. J. Neurosci. Res. 1993, 36:663-671.
23. Iwasaki Y., Ikeda K. Prevention by insulin-like growth factor-I and riluzole in motor neuron death after neonatal axotomy. J. Neurol. Sci. 1999, 169:148-155.
24. Johnston A.M., Pirola L., van Obberghen E. Molecular mechanisms of insulin receptor substrate protein-mediated modulation of insulin signaling. FEBS Lett. 2003, 546:32-36.
25. Kang J.S., Deluca P.P., Lee K.C. Emerging PEGylated drugs. Expert Opin. Emerg. Drugs 2009, 14:363-380.
26. Kaspar B.K., Lladó J., Sherkat N., Rothstein J.D., Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003, 301:839-842.
27. Kennel P., Revah F., Bohme G.A., Bejuit R., Gallix P., Stutzmann J.M., Imperato A., Pratt J. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). J. Neurol. Sci. 2000, 180:55-61.
28. Dy-w mice, a model for congenital muscular dystrophy type 1A. Hum. Mol. Genet. 2011, 20:2333-2343.
29. Lai E.C., Felice K.J., Festoff B.W., Gawel M.J., Gelinas D.F., Kratz R., Murphy M.F., Natter H.M., Norris F.H., Rudnicki S.A. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I study group. Neurology 1997, 49:1621-1630.
30. Lepore A.C., Haenggeli C., Gasmi M., Bishop K.M., Bartus R.T., Maragakis N.J., Rothstein J.D. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2007, 1185:256-265.
31. Lesbordes J.C., Bordet T., Haase G., Castelnau-Ptakhine L., Rouhani S., Gilgenkrantz H., Kahn A. In vivo electrotransfer of the cardiotrophin-1 gene into skeletal muscle slows down progression of motor neuron degeneration in pmn mice. Hum. Mol. Genet. 2002, 11:1615-1625.
32. Lewis M.E., Neff N.T., Contreras P.C., Stong D.B., Oppenheim R.W., Grebow P.E., Vaught J.L. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp. Neurol. 1993, 124:73-88.
33. Martin N., Jaubert J., Gounon P., Salido E., Haase G., Szatanik M., Guenet J.L. A missense mutation in Tbce causes progressive motor neuronopathy in mice. Nat. Genet. 2002, 32:443-447.
34. Masiakowski P., Liu H.X., Radziejewski C., Lottspeich F., Oberthuer W., Wong V., Lindsay R.M., Furth M.E., Panayotatos N. Recombinant human and rat ciliary neurotrophic factors. J. Neurochem. 1991, 57:1003-1012.
35. Masu Y., Wolf E., Holtmann B., Sendtner M., Brem G., Thoenen H. Disruption of the CNTF gene results in motor neuron degeneration. Nature 1993, 365:27-32.
36. Metzger F., Sajid W., Saenger S., Staudenmaier C., van der Poel C., Sobottka B., Schuler A., Sawitzky M., Poirier R., Tuerck D., Schick E., Schaubmar A., Hesse F., Amrein K., Loetscher H., Lynch G.S., Hoeflich A., De Meyts P., Schoenfeld H.-J. Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I. J. Biol. Chem. 2011, 286:19501-19510.
37. Nagano I., Ilieva H., Shiote M., Murakami T., Yokoyama M., Shoji M., Abe K. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J. Neurol. Sci. 2005, 235:61-68.
38. Nagano I., Shiote M., Murakami T., Kamada H., Hamakawa Y., Matsubara E., Yokoyama M., Moritaz K., Shoji M., Abe K. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol. Res. 2005, 27:768-772.
39. Narai H., Nagano I., Ilieva H., Shiote M., Nagata T., Hayashi T., Shoji M., Abe K. Prevention of spinal motor neuron death by insulin-like growth factor-1 associating with the signal transduction systems in SODG93A transgenic mice. J. Neurosci. Res. 2005, 82:452-457.
40. Neff N.T., Prevette D., Houenou L.J., Lewis M.E., Glicksman M.A., Yin Q.W., Oppenheim R.W. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J. Neurobiol. 1993, 24:1578-1588.
41. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N., Yancopoulos G.D., Glass D.J. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 2001, 3:1009-1013.
42. Saenger S., Goeldner C., Frey J.R., Ozmen L., Ostrowitzki S., Spooren W., Ballard T.M., Prinssen E., Borroni E., Metzger F. PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders. Growth Horm. IGF Res. 2011, 21:292-303.
43. Sagot Y., Rosse T., Vejsada R., Perrelet D., Kato A.C. Differential effects of neurotrophic factors on motoneuron retrograde labeling in a murine model of motoneuron disease. J. Neurosci. 1998, 18:1132-1141.
44. Sagot Y., Toni N., Perrelet D., Lurot S., King B., Rixner H., Mattenberger L., Waldmeier P.C., Kato A.C. An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease. Br. J. Pharmacol. 2000, 131:721-728.
45. Schertzer J.D., Ryall J.G., Lynch G.S. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E499-E505.
46. Schmalbruch H., Jensen H.J., Bjaerg M., Kamieniecka Z., Kurland L. A new mouse mutant with progressive motor neuronopathy. J. Neuropathol. Exp. Neurol. 1991, 50:192-204.
47. Sendtner M., Schmalbruch H., Stöckli K.A., Carroll P., Kreutzberg G.W., Thoenen H. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature 1992, 358:502-504.
48. Sendtner M., Stöckli K.A., Thoenen H. Synthesis and localization of ciliary neurotrophic factor in the sciatic nerve of the adult rat after lesion and during regeneration. J. Cell Biol. 1992, 118:139-148.
49. Sendtner M., Götz R., Holtmann B., Thoenen H. Endogenous ciliary neurotrophic factor is a lesion factor for axotomized motoneurons in adult mice. J. Neurosci. 1997, 17:6999-7006.
50. Simonin Y., Perrin F.E., Kato A.C. Axonal involvement in the Wlds neuroprotective effect: analysis of pure motoneurons in a mouse model protected from motor neuron disease at a pre-symptomatic age. J. Neurochem. 2007, 101:530-542.
51. Sorenson E.J., Windbank A.J., Mandrekar J.N., Bamlet W.R., Appel S.H., Armon C., Barkhaus P.E., Bosch P., Boylan K., David W.S., Feldman E., Glass J., Gutmann L., Katz J., King W., Luciano C.A., McCluskey L.F., Nash S., Newman D.S., Pascuzzi R.M., Pioro E., Sams L.J., Scelsa S., Simpson E.P., Subramony S.H., Tiryaki E., Thornton C.A. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008, 71:1770-1775.
52. Tucker K.L., Meyer M., Barde Y.A. Neurotrophins are required for nerve growth during development. Nat. Neurosci. 2001, 4:29-37.
53. Veronese F.M., Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008, 22:315-329.
54. Wagey R., Lurot S., Perrelet D., Pelech S.L., Sagot Y., Krieger C. Phosphatidylinositol 3-kinase activity in murine motoneuron disease: the progressive motor neuropathy mouse. Neuroscience 2001, 103:257-266.
55. Wang Y.J., Hao S.J., Liu Y.D., Hu T., Zhang G.F., Zhang X., Qi Q.S., Ma G.H., Su Z.G. PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: a comparison with glycosylated erythropoietin. J. Control. Release 2010, 145:306-313.
56. Wiese S., Herrmann T., Drepper C., Jablonka S., Funk N., Klausmeyer A., Rogers M.L., Rush R., Sendtner M. Isolation and enrichment of embryonic mouse motoneurons from the lumbar spinal cord of individual mouse embryos. Nat. Protoc. 2010, 5:31-38.
57. Zick Y. Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol. 2001, 11:437-441.